2026-02-26 14:02Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [24] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [24] - Gross margin improved to 87% from approximately 84% in the prior year, reflecting favorable product mix and cost efficiencies [26][27] - Operating expenses grew by 12% to $4.2 billion, with income from operations totaling $447 million, showcasing profitability [28] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, with U.S. sales of $845 million in Q4, driven by a volume growth of approximately 30% [24] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [25] - In-licensed products showed a 9% year-over-year growth, contributing to solid execution across geographies [25] Market Data and Key Metrics Changes - The U.S. remains the largest market, generating $850 million with a year-over-year growth of 38% [25] - China revenue totaled $399 million, an 11% increase compared to Q4 2024, supported by market leadership of TEVIMBRA and BRUKINSA [26] - Europe contributed $174 million, with a 53% year-over-year growth, as BRUKINSA continues its launch trajectory [26] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL and expand across hematological malignancies and solid tumors [37] - Plans to advance one to two cornerstone immunology assets towards registration, indicating a strategic shift towards immunology [37] - The company believes it can move faster and achieve better outcomes across other diseases, leveraging its foundational CLL franchise [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiated value proposition of BRUKINSA, emphasizing its safety profile and long-term efficacy [52] - The company anticipates continued strong demand growth in the U.S. with stable net pricing, projecting 2026 revenue between $6.2 billion and $6.4 billion [30] - Management highlighted the importance of addressing unmet medical needs with new product launches, including sonrotoclax and zanidatamab [30] Other Important Information - The company reported a non-recurring $40 million equity investment impairment in Q4, impacting net income [28] - Free cash flow was over $940 million for the full year 2025, indicating strong cash generation [29] - The company is optimistic about the potential of its new pipeline assets, including a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy [40] Q&A Session Summary Question: Potential net pricing development in the BTK inhibitor market - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which should mitigate pricing pressures from competitors entering the market [51][52] Question: Guidance assumptions regarding competition from AV or Jaypirca - Management noted that AV's clinical profile does not meet the standards for treatment in CLL, and they remain confident in BRUKINSA's position [56] Question: Strategy for immunology pipeline development - The company aims to identify 1 or 2 cornerstone assets in immunology over the next few years, with a focus on being first or best in class [61][63] Question: Impact of ZS becoming the fixed duration regimen of choice on BRUKINSA revenues - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, potentially expanding overall market share [68][70] Question: Update on BTK degrader approval timeline - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [76]